The coronavirus has thrust many previously unknown pharma companies into the spotlight. You can certainly place Sorrento Therapeutics (SRNE) on this list. The company’s unique approach to fighting COVID-19 has resulted in sky scraping surges, yet it hasn’t all been plain sailing. The Yale School of Public has recently won an FDA emergency approval for its saliva-based diagnostic test, which puts it ahead of Sorrento’s COVI-TRACE. Adding more fuel to fire, Sorrento announced the ousting of its chief financial officer. In reaction, investors got cold feet, sending shares tumbling nearly 35% in the past two weeks. Sorrento’s playbook for fighting …read more
Source:: Yahoo Finance
